Clinical trials: Relapsed and Refractory Multiple Myeloma
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Myeloma Multiple, Myeloma
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple…
- Conditions
- Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
- Trial name
- ClaSPd (NCT04843579)
- Testing
- Selinexor, Clarithromycin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Relapsed Refractory Multiple Myeloma
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-002 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting…
- Trial name
- NCT04505813
- Testing
- NEXI-002 T Cells
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- NexImmune Inc.
Leukemia, Lymphoma
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005854
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 4 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Multiple Myeloma
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have demonstrated significant anti-myeloma effects in preclinical lab and animal studies.
- Trial name
- NCT01495351
- Testing
- ABT-888/Bortezomib
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- AHS Cancer Control Alberta
Myeloma Multiple
Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
[Purpose] This study aims to assess the efficacy of immunotherapeutic agents in real clinical settings by comparing the treatment outcomes of relapsed/refractory multiple myeloma patients treated with immunotherapeutic agents and…
- Trial name
- CAREMM-2305 (NCT06205823)
- Testing
- Immunotherapy
- Where
- South Korea
- Volunteers
- 1,600 people
- Sponsor
- Seoul St. Mary's Hospital
Multiple Myeloma Bone Disease
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
This study has two portions, a phase I portion and a phase II portion. The purpose of the phase I portion is to assess the maximum-tolerated dose (MTD) and to characterize dose limiting toxicity (DLT) of escalating doses of…
- Trial name
- NCT00741377
- Testing
- BHQ880, Zoledronic acid
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003451
- Testing
- recombinant interferon alfa, recombinant interleukin-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants…
- Trial name
- NCT06742138
- Testing
- QL2109, Pomalidomide, Dexamethasone
- Volunteers
- 284 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT01348919
- Testing
- CEP-18770, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States, New Zealand
- Volunteers
- 11 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Advanced Solid Tumors, Lymphoma
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors…
- Conditions
- Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT04214093
- Testing
- AZD0466
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig…
- Trial name
- TRI Pro (NCT07589634)
- Testing
- Ramantamig, Tocilizumab
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560352
- Testing
- Dasatinib, Bortezomib, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma.
- Trial name
- CHUQUL_HO001 (NCT07094048)
- Testing
- Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- CHU de Quebec-Universite Laval
Relapsed or Refractory Multiple Myeloma
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM).
- Trial name
- NCT04706936
- Testing
- anti-BCMA CAR-T, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after…
- Trial name
- NCT06232044
- Testing
- Iberdomide, Belantamab Mafodotin, Dexamethasone
- Where
- 43 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple…
- Trial name
- NCT06163898
- Testing
- Alnuctamab, Mezigdomide, Dexamethasone
- Where
- 6 sites in United States, Israel
- Volunteers
- 4 people
- Sponsor
- Celgene
Relapsed and/or Relapsed-refractory Multiple Myeloma
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen.
- Trial name
- NCT01897714
- Testing
- Melflufen, Dexamethasone
- Where
- 7 sites in United States, Denmark and 3 more
- Volunteers
- 75 people
- Sponsor
- Oncopeptides AB